65,437 trials
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) — -0.027; -0.006; -0.044; -0.033 Liters
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 2.0; 2.7; 1.7; 2.5 Months — p=0.8885
Bacterial Vaginosis
Primary: Cure of Bacterial Vaginosis — 75; 73; 77 participants
Type 1 Diabetes
Primary: Change in HbA1c and Compared Between Groups — -0.3122449; 0.1191489 percent HbA1c — p=<0.05
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Schizophrenia
Primary: Positive and Negative Syndrome Scale (PANSS) Total Score Change From Baseline — 1.40; 4.51; -8.79 Points on a scale
Restless Legs Syndrome
Primary: Change From Baseline in the International Restless Legs Syndrome Rating Scale (IRLS) at Week 52 Using Observed Case (OC) — -16.3; -17.0; -16.8 points on a scale
Hereditary Angioedema
Primary: Time to Start of Relief of Symptoms From HAE Attack (Intent to Treat (ITT) Subject Population) — 0.46 hours
Rheumatoid Arthritis
Primary: Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 — 129; 26 participants — p=<0.001
Breast Cancer
Primary: Disease Free Survival [Number of Events] — 164; 140; 1140; 1167 participants
Open-angle Glaucoma (OAG) · Ocular Hypertension
Primary: Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5 — -9.8; -2.9; -5.0; -6.5 mm Hg
Rheumatoid Arthritis
Primary: Response to Treatment (ACR20) in Adult Patients With Established Rheumatoid Arthritis (RA) — 17; 2; 27; 2 Participants
Sleep Deprivation
Primary: Maintenance of Wakefulness Test (MWT) — 23.3; 27.9; 29.3; 27.6 Minutes — p=<0.0001
HIV Infections
Primary: HIV-1 RNA Level — 1.2; 1.7 copies/mL — p=0.546
Bladder Outlet Obstruction · Lower Urinary Tract Symptoms
Primary: Mean Urine Flow Rate — 12; 13; 16 ml/s — p=0.44